Wuhan Huakang Century Medical Co. Ltd. (301235) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Wuhan Huakang Century Medical Co. Ltd. stock ¥9.58, price ¥29.59, that is 67.6% below the price, quality 48 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
57‑month range ¥14.77 – ¥76.00 · fair‑value band ¥9.58 – ¥13.65 · the ¥29.59 price screens above the ¥9.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Wuhan Huakang Century Medical Co. in your weekly email
Every Wednesday you see whether Wuhan Huakang Century Medical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Wuhan Huakang Century Clean Technology Co., Ltd. provides purification system integration and sale of medical equipment and consumables services in China and internationally. It is also involved in the sale of medical equipment and consumables.
Show moreShow less
In addition, the company offers integrated medical services, laboratory integrated services, and integrated electronic cleaning services, as well as medical consumables sales; purification system integration operation, and maintenance services.
The company was formerly known as Wuhan Huakang Century Medical Co., Ltd. and changed its name to Wuhan Huakang Century Clean Technology Co., Ltd. in March 2025. Wuhan Huakang Century Clean Technology Co., Ltd. was founded in 2008 and is headquartered in Wuhan, China.
Stock analysis
Wuhan Huakang Century Medical Co. Ltd. (301235) currently trades at ¥29.59, while our model-based Fair Value estimate is ¥9.58, 68% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥30.33 per share, and 4 of the 17 models we run sit above the ¥29.59 price.
Bear case: the Dividend Discount group reads lowest at ¥1.58, and 13 of the 17 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥9.58 (bear) to ¥13.65 (bull), the price of ¥29.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Wuhan Huakang Century Medical Co. Ltd. reported revenue of 2.3B CNY in FY2025 versus 861M CNY in FY2021, a compound +27.7%/yr. Reported net income was 118M CNY in FY2025, compounding +9.7%/yr from FY2021.
Key figures
Market cap 4.0B CNY (≈ $599M) Small · P/E ratio 30.5 · P/S ratio 1.61 · EPS (TTM) ¥0.9700 · Dividend yield 0.7% · Net margin 4.6% · Return on equity 6.2% · Return on assets (EBIT) 7.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (medium confidence).
What moves the price
The share trades about 61% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −68%, 301235 screens richer than that median.
Fair Value models
Bear¥9.58Fair Value ¥9.58Bull¥13.65
Price ¥29.59 · Downside -67.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.6582 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+33.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.9%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
Compare Wuhan Huakang Century Medical Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−67.6% · Bottom 25%
Profitability
Return on equity (12 months)6.2% · Above median
Return on assets2.7% · Above median
Net margin (12 months)4.6% · Below median
Operating margin (12 months)5.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)14.5% · Above median
Dividend yield (12 months)0.7% · Bottom 25%
Balance sheet
Debt / equity0.44× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)30.5× · Pricier than median
P/B2.09× · Pricier than median
P/S (12 months)1.61× · Cheaper than median
EV/EBITDA20.9× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)73· sector 35
PAST (return on equity)25· sector 17
HEALTH (low debt)78· sector 98
DIVIDEND (yield)14· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Wuhan Huakang Century Medical Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/301235
Frequently asked questions
Is Wuhan Huakang Century Medical Co. Ltd. (301235) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥9.58 versus a price of ¥29.59, about 68% lower (overvalued).
What is the fair value of 301235?
Our model-based fair value for Wuhan Huakang Century Medical Co. Ltd. is ¥9.58 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥29.59.
What is the quality score of 301235?
Wuhan Huakang Century Medical Co. Ltd. has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Wuhan Huakang Century Medical Co. Ltd. (301235)?
Our model-based price target is the fair value of ¥9.58 (as of Nov 7, 2026) from 17 valuation models. Cautious scenario ¥9.58, optimistic scenario ¥13.65. It is a calculation from audited fundamentals, not an analyst target.
What is the Wuhan Huakang Century Medical Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥9.58, about 68% lower versus a price of ¥29.59 (overvalued). Cautious scenario ¥9.58, optimistic scenario ¥13.65. The calculation is refreshed regularly with new filings.
What is the revenue of Wuhan Huakang Century Medical Co. Ltd. (301235)?
Wuhan Huakang Century Medical Co. Ltd. reported trailing-twelve-month revenue of about 2.5B CNY (latest available figure, as of Nov 7, 2026).
Does Wuhan Huakang Century Medical Co. Ltd. pay a dividend?
Wuhan Huakang Century Medical Co. Ltd. currently shows a dividend yield of 0.68% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Wuhan Huakang Century Medical Co. Ltd. (301235) and when is the ex-dividend date?
Wuhan Huakang Century Medical Co. Ltd. pays a dividend of ¥0.2 per share a year, a dividend yield of 0.7%. The last ex-dividend date was May 29, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 20.6% of earnings. Our assessment: Token dividend. At a yield of 0.7% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.7% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Wuhan Huakang Century Medical Co. Ltd. (301235)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Wuhan Huakang Century Medical Co. Ltd. it is ¥9.58 per share (as of Nov 7, 2026), against a price of ¥29.59. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Wuhan Huakang Century Medical Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 301235 trades above its calculated fair value: price ¥29.59, fair value ¥9.58, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301235?
No. The price is what the market pays today (¥29.59); the fair value is what the company's own numbers justify (¥9.58). For Wuhan Huakang Century Medical Co. Ltd. the two are ¥20.01 per share apart. That gap is exactly why we show both numbers side by side.
How much is Wuhan Huakang Century Medical Co. Ltd. worth?
The market values Wuhan Huakang Century Medical Co. Ltd. at about 4.0B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥29.59; our models calculate a fair value of ¥9.58 per share.
What do the bullish and bearish scenarios say about 301235?
Our models span a range for Wuhan Huakang Century Medical Co. Ltd.: cautious scenario ¥9.58, base ¥9.58, optimistic ¥13.65 per share (as of Nov 7, 2026, price ¥29.59). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 301235?
Wuhan Huakang Century Medical Co. Ltd. trades at a price-to-earnings ratio of 30.5 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥9.58 is built from several models across several years. Other multiples: P/B 2.1, P/S 1.6, EV/EBITDA 20.9.
How solid is the balance sheet of Wuhan Huakang Century Medical Co. Ltd. (301235)?
Balance-sheet figures for Wuhan Huakang Century Medical Co. Ltd. (as of Nov 7, 2026): return on equity 6.2%, debt of 0.44 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 301235 from its 52-week high?
Wuhan Huakang Century Medical Co. Ltd. trades at ¥29.59, about 61% below its 52-week high of ¥76.00 and 5% above the low of ¥28.25 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥9.58 is for.
Which stocks are comparable to Wuhan Huakang Century Medical Co. Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Wuhan Huakang Century Medical Co. Ltd. stock attractive at the current price?
The data as of Nov 7, 2026: price ¥29.59, calculated fair value ¥9.58 (−68%), Quality Score 48/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301235 calculated?
We run Wuhan Huakang Century Medical Co. Ltd. through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥9.58 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Wuhan Huakang Century Medical Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Wuhan Huakang Century Medical Co. Ltd. (301235)?
The closing price on Nov 6, 2026 was ¥29.59. Our model-based fair value is ¥9.58, about 68% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Wuhan Huakang Century Medical Co. Ltd. right now?
The price sits above even our optimistic bull case (¥13.65). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Wuhan Huakang Century Medical Co. Ltd.
How large is the market capitalisation of Wuhan Huakang Century Medical Co. Ltd. (301235)?
The market capitalisation of Wuhan Huakang Century Medical Co. Ltd. is 4.0B CNY (≈ $599M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Wuhan Huakang Century Medical Co. Ltd. (301235)?
The price-to-sales ratio of Wuhan Huakang Century Medical Co. Ltd. is 1.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Wuhan Huakang Century Medical Co. Ltd. (301235)?
Earnings per share at Wuhan Huakang Century Medical Co. Ltd. are ¥0.9700 (price ÷ EPS = P/E 30.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Wuhan Huakang Century Medical Co. Ltd. (301235)?
The dividend yield of Wuhan Huakang Century Medical Co. Ltd. is 0.7% (payout 20.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Wuhan Huakang Century Medical Co. Ltd. (301235)?
The net margin of Wuhan Huakang Century Medical Co. Ltd. is 4.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Wuhan Huakang Century Medical Co. Ltd. (301235)?
The return on equity (ROE) of Wuhan Huakang Century Medical Co. Ltd. is 6.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Wuhan Huakang Century Medical Co. Ltd. (301235)?
On an EBIT basis the return on assets of Wuhan Huakang Century Medical Co. Ltd. is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Wuhan Huakang Century Medical Co. Ltd. (301235)?
The operating margin of Wuhan Huakang Century Medical Co. Ltd. is 5.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Wuhan Huakang Century Medical Co. Ltd. (301235)?
Revenue at Wuhan Huakang Century Medical Co. Ltd. is growing +14.5% versus a year earlier (3y avg +24.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Wuhan Huakang Century Medical Co. Ltd. (301235)?
Earnings per share at Wuhan Huakang Century Medical Co. Ltd. are growing −49.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Wuhan Huakang Century Medical Co. Ltd. (301235) generate?
The free cash flow of Wuhan Huakang Century Medical Co. Ltd. is −156M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Wuhan Huakang Century Medical Co. Ltd. (301235) carry?
The net debt of Wuhan Huakang Century Medical Co. Ltd. is 324M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Wuhan Huakang Century Medical Co. Ltd. in the live analysis
One click puts Wuhan Huakang Century Medical Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026